Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                About Science & Research at FDA

About Science & Research at FDA

                        Emerging Sciences
          Public Access to Results of FDA-Funded Scientific Research
          Scientific Integrity at FDA
          FDA Sexual Harassment Policy Concerning Extramural Research
          Medical Product Development Tools at FDA
          Modeling & Simulation at FDA
          FDA's Predictive Toxicology Roadmap


                        Advancing Alternative Methods at FDA
          FDA Grand Rounds
          The FDA Science Forum Home
          Science & Research
          About Science & Research at FDA
          FDA Sexual Harassment Policy Concerning Extramural ResearchAbout Science & Research at FDA FDA Sexual Harassment Policy Concerning Extramural Research
  
  	
    Share
    Post
    Linkedin

    Email
    PrintAnti-Sexual Harassment

The Food and Drug Administration (FDA) is committed to supporting a safe and respectful work environment. To that end, FDA maintains requirements and recommendations for institutions and individuals supported by FDA-funded grant awards.

FDA’s Commitment

What is sexual harassment?

Actions contributing to sexual harassment include unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature. Sexual harassment can be committed by anyone — men or women, against men or women, and by a supervisor, co-worker, subordinate, or non-employee.

In Education, sexual harassment is actionable under Title IX when it is so severe, pervasive, and objectively offensive, that it undermines and detracts from the victims’ educational experience, such that the victims are effectively denied equal access to an institution's resources and opportunities.*

In Employment, sexual harassment is unlawful when it is so severe and pervasive that a reasonable person would consider it a hostile or intimidating work environment or when enduring the offensive conduct becomes a condition of continued employment.

*Davis v. Monroe County Board of Education, 526 U.S. 629, 649 (1999).

In supporting a safe and respectful work environment, FDA does not tolerate harassment of any kind, including sexual harassment at institutions that receive FDA grant funding, or anywhere that FDA-grant funded activities are conducted.

FDA’s Requirements and Recommendations

Consistent with HHS grants regulations (45 C.F.R. Part 75), and the HHS Grants Policy Statement (which is incorporated by reference as a term and condition of all FDA grant awards), FDA requires that every organization receiving FDA grant funds:

Have policies and procedures in place to manage grant activities in accordance with Federal laws, regulations, and policies protecting the rights and safety of individuals working on FDA-grant funded projects.
	Notify FDA if an organization takes an administrative or disciplinary action against a principal investigator or other senior key personnel that affects their ability to continue in their capacity on an FDA grant award.FDA grant recipients must also comply with applicable Federal civil rights laws prohibiting discrimination on the basis of sex, including Section 1557 of ACA, which prohibits discrimination by health programs and activities receiving Federal financial assistance (including health-related research), and Title IX of the Education Amendments Act, which prohibits discrimination on the basis of sex in educational programs and activities receiving Federal financial assistance. If sufficiently severe, sexual harassment is a type of sex discrimination that violates these laws. FDA grant recipients have also provided an assurance, when signing the HHS-690 form, that they will comply with these laws.

Consistent with the HHS Grants Policy Statement, which is incorporated by reference as a term and condition of all FDA grant awards, recipients of FDA funds must immediately notify FDA of changes in a principal investigator’s status, (e.g. modified employment or leave status during an investigation of alleged sexual misconduct.)

The organization receiving FDA grant funding must notify FDA if it takes an administrative or disciplinary action against a principal investigator or other senior key personnel, e.g. limiting access to the institution’s facilities or resources, modifying employment or leave status during an investigation of alleged sexual misconduct, and anything else that affects the ability of the principal investigator or other senior key personnel on an FDA grant award to continue in their capacity.FDA recommends that every organization receiving FDA grant funds:

Develop and implement policies and practices that ensure a harassment-free environment;
	Maintain clear, unambiguous professional codes of conduct;
	Ensure that employees are fully aware and regularly reminded of applicable laws, regulations, policies, and codes of conduct;
	Provide an accessible, effective, and easy process to report sexual harassment and provide protection from retaliation;
	Respond promptly to allegations to ensure the immediate safety of all involved, investigate the allegations, and take appropriate actions; and
	Take steps to maintain a safe and respectful environment for all attendees at a conference supported by an FDA conference grant (R13/U13), by providing an environment free from discrimination and harassment, sexual or otherwise.

FDA encourages organizations receiving FDA grant funds to have in place similarly rigorous policies and related procedures for employees, contractors, trainees, fellows, and any other personnel who engage in agency-funded activities.

FDA uses the compliance and oversight tools within its authority to support a safe, harassment-free work environment, while respecting the multitude of Federal, state, and local laws and policies that govern how sexual harassment allegations are adjudicated.

Outlined below are FDA policies and requirements that support these efforts: a description of the current reviews FDA conducts before an award is made and FDA post-award management and actions.

FDA Actions and Oversight

Pre-Award Actions

When an organization submits a grant application to FDA, its Authorized Organization Representative signs the application, certifying that the organization will comply with all applicable policies, assurances and/or certifications referenced in the application. Some of these stipulations require that a separate document be submitted to the appropriate Federal office, including submission of civil rights assurance to the Office of Civil Rights.

FDA conducts a pre-award risk assessment for every applicant organization by checking multiple Federal-wide systems used for management and oversight of Federal funding recipients. This includes, but is not limited to the Federal System for Award Management (SAM), among other resources, to determine if a recipient is eligible to receive an FDA grant award. FDA also queries the Federal Awardee Performance and Integrity Information System (FAPIIS) and the National External Audit Review center (NEAR) to determine if the applicant organization is eligible and qualified to receive an FDA grant award. FDA reports all information on non-compliance into these systems, including violations of the HHS Grants Policy Statement or violations of Federal laws and regulations, such as civil rights protections.

Post-Award Actions

If FDA indirectly learns of an allegation of sexual harassment, we immediately alert the recipient institution to verify issues and take all appropriate actions. If senior/key personnel on an FDA-funded grant are not in compliance with applicable laws, and regulations, FDA can take several actions against the institution. These actions include requiring a change in senior personnel or remedies for noncompliance, such as suspension or termination of the grant award, consistent with applicable regulations, 45 C.F.R. Part 75, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for HHS Awards.

While FDA does not have jurisdiction to intervene in personnel matters at third-party organizations, FDA takes all allegations of sexual harassment very seriously and requires that grantee institutions foster work environments conducive to high-quality research, a term and condition of FDA award. FDA urges people to report allegations to the appropriate authorities.

                                                                                  Content current as of:
      02/28/2020About Science & Research at FDA

          
                        Emerging Sciences
          Public Access to Results of FDA-Funded Scientific Research
          Scientific Integrity at FDA
          FDA Sexual Harassment Policy Concerning Extramural Research
          Medical Product Development Tools at FDA
          Modeling & Simulation
          FDA's Predictive Toxicology Roadmap


                        Advancing Alternative Methods at FDA
          FDA Grand Rounds
          The FDA Science Forum
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop